This is Why Wall Street Firms are Bullish on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the best blue-chip stocks to buy for 2026. Boston Scientific Corporation (NYSE:BSX) said on January 12 that it has agreed to acquire Valencia Technologies, maker of the FDA-approved eCoin System for urge urinary incontinence. The coin-sized implant, placed near the ankle, uses tibial nerve stimulation to help control bladder activity and showed a 68% response rate in clinical trials. The acquisition expands Boston Scientific’s urology and pelvic health portfolio with implantable tibial nerve stimulation technology. The deal is expected to close in the first half of 2026, with no disclosed financial terms and minimal impact on adjusted earnings.

On January 6, JPMorgan reiterated Boston Scientific Corporation (NYSE:BSX) is one of its top pick stocks in the healthcare sector. According to the investment bank, the company is well-positioned in the medical device market.

Backed by cardiovascular, rhythm management, and endoscopy product lines, Boston Scientific has etched its name as a leader in minimally invasive medical technologies. That was the catalyst behind the company delivering third-quarter revenue that was above analyst expectations.

Likewise, UBS reiterated a Buy rating on the stock on December 17 and set a $140 price target. According to analyst Danielle Antalffy, the stock’s risk-reward profile is skewed to the upside given the high-growth businesses in play. Chief Executive Officer Mike Mahoney has already reiterated plans to grow the Electrophysiology (EP) division, which accounts for 17% of sales, to 20-25%.

UBS expects the medical devices company to guide 2026 sales growth above its long-range plan of 10% to 12%. Most of the growth would be driven by strong momentum in the WATCHMAN business.

Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets a wide range of innovative medical devices and solutions used by healthcare professionals worldwide to diagnose and treat complex conditions in areas such as cardiology, endoscopy, oncology, urology, and neuromodulation, with a focus on improving patient outcomes and advancing less-invasive medicine.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Penny Stocks to Buy for 2026 and 10 Best Metal Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.